Author’s response to reviews

Title: Clinical Management of Malignant Insulinoma: A Single Institution’s Experience over Three Decades

Authors:

Jie Yu (bailubailing@163.com)
Pan Ping (pingfan6779@163.com)
Huabing Zhang (huabingzhang@sina.com)
Wei Li (WeiLi43@163.com)
Tao Yuan (yuan3750057@163.com)
Yong Fu (YongFu057@163.com)
Kai Feng (KaiFeng0695@163.com)
Weibo Xia (WeiboXia357@126.com)
Lingling Xu (llxuwsh@163.com)
Yuxiu Li (liyuxiu@medmail.com.cn)

Version: 1 Date: 24 Jun 2018

Author’s response to reviews:

1. You appear to have searched medical records, this would not constitute a literature review and appears to be a retrospective case review, therefore please change your title to better describe your study.

--Yes, we have changed the title.

2. Please clarify whether you received ethics committee approval, if ethics approval has been waived please clarify if the hospital ethics committee approved this and please provide the reason why in your manuscript.

--Yes, we have received ethics committee approval from PUMCH.
3. Please clarify whether you received consent to publish from the individuals in question. You have presented their clinical data in table 1. Please blind this table if you do not have consent to publish by providing age ranges rather than specific details.

--The study was exempt from written informed consent due to its retrospective design

4. Please ensure you comply with STROBE guidelines for observational studies and provide a completed checklist as a supplementary file with your submission.

--Yes, we have checked the STROBE guidelines and completed the checklist.

5. Please clarify if the values in Table 2 are mean or median values. Please ensure that you make Table 2 clearer.

--Yes, we have revised the Table 2.